# A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct07389733/  
OnCo record `nct07389733` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HRS-8080 and Fulvestrant in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.

## Summary

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT07389733 by Shandong Suncadia Medicine Co., Ltd., with 180 participants planned, started 2026-03-27 and due to reach its primary completion in 2028-12. Interventions recorded: HRS-6208 Capsule, HRS-6209 Capsule, HRS-8080 Tablet, Fulvestrant injection and Letrozole tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07389733
- Phase: 1/2
- Setting: Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-6208 in Combination With HRS-8080 ± HRS-6209, or in Combination With Fulvestrant ± HRS-6209, or in Combination With Letrozole ± HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer: an Open Label, Multicenter, Phase Ib/II Study
- Sponsor: Shandong Suncadia Medicine Co., Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07389733: https://clinicaltrials.gov/study/NCT07389733

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [HRS-8080](https://onco.cc/drugs/hrs-8080/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07389733.json